我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
已完成
3
50.0%
招募中
暂停
暂无批准数据
- Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability. - The trial assessed the safety, tolerability, and pharmacokinetics of ANT3310, a serine-beta-lactamase inhibitor, both alone and in combination with meropenem. - Results indicate that ANT3310 was well-tolerated with no serious adverse events and exhibited compatible pharmacokinetics with meropenem, supporting further patient studies. - MEM-ANT3310 is designed to combat antimicrobial resistance in severe hospital infections, particularly those caused by Gram-negative pathogens like CRAB, CRE, and Pseudomonas aeruginosa.
